Search research articles
Contact Us
Filters
Showing results (61-70 of 120) with videos related to
Page
of 12
Sort By:
Plos One
|
July 9, 2016
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
Josep M Llibre, François Raffi, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy
|
May 9, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
Emilie R Elliot, Alieu Amara, Nicole Pagani, et al.
The Journal of Antimicrobial Chemotherapy
|
April 14, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
Emilie R Elliot, Alieu Amara, Nicole Pagani, et al.
Plos One
|
May 20, 2016
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
Josep M Llibre, François Raffi, Graeme Moyle, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 18, 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Julian Falutz, Jean-Claude Mamputu, Diane Potvin, et al.
HIV Research & Clinical Practice
|
September 23, 2021
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients
Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, et al.
The Journal of Antimicrobial Chemotherapy
|
September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
Jennifer Ford, Marta Boffito, Desmond Maitland, et al.
The Journal of Antimicrobial Chemotherapy
|
February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
Marta Boffito, Desmond Maitland, Laura Dickinson, et al.
Antiviral Therapy
|
January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects
Akil Jackson, Graeme Moyle, Laura Dickinson, et al.
Antimicrobial Agents and Chemotherapy
|
June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients
Jennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 120) with videos related to
Sort By:
Page
of 12
Plos One
|
July 9, 2016
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
Josep M Llibre, François Raffi, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy
|
May 9, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
Emilie R Elliot, Alieu Amara, Nicole Pagani, et al.
The Journal of Antimicrobial Chemotherapy
|
April 14, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
Emilie R Elliot, Alieu Amara, Nicole Pagani, et al.
Plos One
|
May 20, 2016
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
Josep M Llibre, François Raffi, Graeme Moyle, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 18, 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Julian Falutz, Jean-Claude Mamputu, Diane Potvin, et al.
HIV Research & Clinical Practice
|
September 23, 2021
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients
Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, et al.
The Journal of Antimicrobial Chemotherapy
|
September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
Jennifer Ford, Marta Boffito, Desmond Maitland, et al.
The Journal of Antimicrobial Chemotherapy
|
February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
Marta Boffito, Desmond Maitland, Laura Dickinson, et al.
Antiviral Therapy
|
January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects
Akil Jackson, Graeme Moyle, Laura Dickinson, et al.
Antimicrobial Agents and Chemotherapy
|
June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients
Jennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Page
of 12